KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Accumulated Expenses (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Accumulated Expenses readings, the most recent being $11.9 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 6.27% to $11.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.9 million, a 6.27% decrease, with the full-year FY2025 number at $11.9 million, down 6.27% from a year prior.
  • Accumulated Expenses hit $11.9 million in Q4 2025 for Esperion Therapeutics, down from $18.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $34.5 million in Q3 2021 to a low of $3.4 million in Q2 2024.
  • Median Accumulated Expenses over the past 5 years was $8.4 million (2022), compared with a mean of $12.1 million.
  • Biggest five-year swings in Accumulated Expenses: tumbled 81.57% in 2023 and later soared 425.69% in 2025.
  • Esperion Therapeutics' Accumulated Expenses stood at $7.0 million in 2021, then fell by 22.63% to $5.4 million in 2022, then skyrocketed by 98.47% to $10.8 million in 2023, then increased by 18.29% to $12.7 million in 2024, then dropped by 6.27% to $11.9 million in 2025.
  • The last three reported values for Accumulated Expenses were $11.9 million (Q4 2025), $18.6 million (Q3 2025), and $8.4 million (Q2 2025) per Business Quant data.